The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...
For patients with diffuse large B-cell lymphoma (DLBCL), the detection of circulating tumor DNA (ctDNA) following first-line treatment is independently predictive of disease recurrence and overall ...
4hon MSN
First in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...
Lyell Immunopharma, Inc. announced promising clinical data for its CAR T-cell therapy candidate LYL314, showing an 88% overall response rate and a 72% complete response rate in patients with relapsed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results